Navigation Links
News brief: Knockdown of E2F1 reduces invasive potential of melanoma cells
Date:12/23/2009

Inhibition of transcription factor E2F1 reduced epidermal growth factor receptor (EGFR) expression and reduced the invasive potential but not proliferation of metastatic melanoma cells, according to a brief communication published online December 23 in the Journal of the National Cancer Institute.

To investigate E2F1's role in cancer progression, Brigitte M. Ptzer, M.D., Ph.D., of the department of vectorology and experimental gene therapy at the University Rostock in Germany, and colleagues used E2F1 gene silencing in melanoma cells and in mice to compare cell growth and invasive potential and tumor growth and formation of metastatic lesions. The authors also examined expression of EGFR, a protein previously found to be associated with cancer progression, and effects of its inhibition.

Melanoma cells with reduced E2F1 expression had lower invasive potential even though they grew at the same rate as control cells. Tumors in animals with reduced E2F1 expression grew at similar rates, but formed fewer and metastatic lesions than control tumors. EGFR expression was decreased in E2F1-silenced cells, and its inhibition reduced the invasive potential of these cells.

"Because elevated expression of E2F1 and EGFR has been observed in other tumor types, the established mechanistic link may also be important in other human cancers," the authors write. "This association should be explored in future studies."

Study limitations: Because the study was based on specific in vitro and in vivo models, it is still unclear whether these mechanisms are useful targets in human cancer.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. News brief: Dermatologic infections in cancer patients treated with EGFRI therapy
2. News brief: Long-term testicular cancer survivors at high risk for neurological side effects
3. News brief: Estrogen receptor-alpha, breast cancer patients and tamoxifen response
4. News brief: Arsenic biomethylation required for oxidative DNA damage
5. News brief: Adverse symptom reporting by patients vs. clinicians
6. News brief: Effects of aspirin and folic acid on inflammation markers for colorectal adenomas
7. JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer
8. JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
9. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
10. JNCI news brief: High serum insulin levels and risk of prostate cancer
11. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
Breaking Medicine Technology: